Overview

C-CAR066 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The goal of this multicenter study is to test C-CAR066 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: - is C-CAR066 safe and do patients tolerate it well? - what is the best dose of C-CAR066? - will C-CAR066 help patients achieve a response and for how long?
Phase:
Phase 1
Details
Lead Sponsor:
Cellular Biomedicine Group, Inc.
Collaborator:
Mayo Clinic